EP3082427A4 - Compositions et méthodes destinées à traiter le glaucome - Google Patents

Compositions et méthodes destinées à traiter le glaucome Download PDF

Info

Publication number
EP3082427A4
EP3082427A4 EP14872240.8A EP14872240A EP3082427A4 EP 3082427 A4 EP3082427 A4 EP 3082427A4 EP 14872240 A EP14872240 A EP 14872240A EP 3082427 A4 EP3082427 A4 EP 3082427A4
Authority
EP
European Patent Office
Prior art keywords
glaucoma
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14872240.8A
Other languages
German (de)
English (en)
Other versions
EP3082427A1 (fr
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GNT LLC
Original Assignee
GNT LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/132,780 external-priority patent/US20140107173A1/en
Application filed by GNT LLC filed Critical GNT LLC
Publication of EP3082427A1 publication Critical patent/EP3082427A1/fr
Publication of EP3082427A4 publication Critical patent/EP3082427A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
EP14872240.8A 2013-12-18 2014-02-11 Compositions et méthodes destinées à traiter le glaucome Withdrawn EP3082427A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/132,780 US20140107173A1 (en) 2011-02-03 2013-12-18 Compositions and Methods for Treatment of Glaucoma
PCT/US2014/015797 WO2015094392A1 (fr) 2013-12-18 2014-02-11 Compositions et méthodes destinées à traiter le glaucome

Publications (2)

Publication Number Publication Date
EP3082427A1 EP3082427A1 (fr) 2016-10-26
EP3082427A4 true EP3082427A4 (fr) 2017-08-02

Family

ID=53403464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14872240.8A Withdrawn EP3082427A4 (fr) 2013-12-18 2014-02-11 Compositions et méthodes destinées à traiter le glaucome

Country Status (7)

Country Link
EP (1) EP3082427A4 (fr)
JP (1) JP2017501224A (fr)
CN (1) CN106455567A (fr)
BR (1) BR112016014404A2 (fr)
CA (1) CA2934453A1 (fr)
MX (1) MX2016007902A (fr)
WO (1) WO2015094392A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160548A1 (fr) * 2016-03-17 2017-09-21 Presbyopia Therapies, LLC Compositions et méthodes de traitement de la presbytie
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112107544A (zh) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN115137699B (zh) * 2021-03-29 2024-05-03 四川普锐特药业有限公司 一种增效防腐的右美托咪定鼻喷剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106537A1 (fr) * 2011-02-03 2012-08-09 Alpha Synergy Development, Inc. Compositions et procédés pour le traitement du glaucome
US20130172357A1 (en) * 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
WO2013115844A1 (fr) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions et méthodes destinées à traiter le glaucome
WO2014204791A1 (fr) * 2013-06-21 2014-12-24 Gnt, Llc Compositions de véhicules d'administration lipophiles et hydrophiles pour médicaments ophtalmiques
WO2015031186A1 (fr) * 2013-08-28 2015-03-05 Presbyopia Theraplies, Llc Compositions et méthodes pour le traitement de la presbytie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
EP1654002B2 (fr) * 2003-08-07 2014-01-29 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
EP2320911B1 (fr) * 2008-08-01 2014-10-08 Eye Therapies LLC Compositions de vasoconstriction, et procédés d'utilisation
CA2782872A1 (fr) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions et methodes d'administration ophtalmique de decongestionnants nasals
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
EP2555748A2 (fr) * 2010-04-07 2013-02-13 Allergan, Inc. Combinaisons de conservateurs pour les compositions ophtalmiques
US20140107173A1 (en) * 2011-02-03 2014-04-17 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
CA2841632A1 (fr) * 2011-07-14 2013-01-17 Allergan, Inc. Compositions de gel d'oxymetazoline et leurs procedes d'utilisation
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106537A1 (fr) * 2011-02-03 2012-08-09 Alpha Synergy Development, Inc. Compositions et procédés pour le traitement du glaucome
US20130172357A1 (en) * 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
WO2013115844A1 (fr) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions et méthodes destinées à traiter le glaucome
WO2014204791A1 (fr) * 2013-06-21 2014-12-24 Gnt, Llc Compositions de véhicules d'administration lipophiles et hydrophiles pour médicaments ophtalmiques
WO2015031186A1 (fr) * 2013-08-28 2015-03-05 Presbyopia Theraplies, Llc Compositions et méthodes pour le traitement de la presbytie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015094392A1 *

Also Published As

Publication number Publication date
JP2017501224A (ja) 2017-01-12
CA2934453A1 (fr) 2015-06-25
MX2016007902A (es) 2016-10-28
WO2015094392A1 (fr) 2015-06-25
BR112016014404A2 (pt) 2017-08-08
CN106455567A (zh) 2017-02-22
EP3082427A1 (fr) 2016-10-26

Similar Documents

Publication Publication Date Title
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
EP3049070A4 (fr) Compositions et méthodes pour le traitement et la prophylaxie de maladies gastro-intestinales
EP2997146A4 (fr) Procédés et compositions pour le traitement d'une maladie génétique
EP3024497A4 (fr) Procédés et compositions pour traiter des maladies du cerveau
EP3071193A4 (fr) Compositions et méthodes de traitement de l'inflammation oculaire et de la douleur
EP3082819A4 (fr) Composés substitués de diaminopyrimidyle, compositions à base de ceux-ci, et méthodes de traitement les utilisant
EP2991946A4 (fr) Compositions correctives contenant de la ponce et procédés d'utilisation
EP3038646A4 (fr) Procédés de diagnostic et compositions pour le traitement d'un glioblastome
EP2958936A4 (fr) Méthodes et compositions pour le traitement de la maladie de forbes-cori
EP2967049A4 (fr) Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine
EP2986113A4 (fr) Compositions et méthodes pour le traitement des lésions cérébrales
HK1224210A1 (zh) 用於治療纖維化的方法和組合物
EP3046581A4 (fr) Compositions et procédés pour le traitement de la microangiopathie thrombotique associée à la transplantation de cellules souches hématopoïétiques (tcsh)
EP3086809A4 (fr) Compositions et procédés de traitement de troubles oculaires
EP3004396A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3082427A4 (fr) Compositions et méthodes destinées à traiter le glaucome
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP3021840A4 (fr) Procédés et compositions pour la prévention d'une réaction allergique
EP3043817A4 (fr) Méthodes et compositions de traitement d'une infection à chlamydia et de maladies et troubles associés
EP3082845A4 (fr) Procédés et compositions pour le traitement de neuropathies périphériques
EP3057596A4 (fr) Compositions et procédés pour les administrer
EP2994147A4 (fr) Compositions et méthodes pour le traitement des acouphènes
EP3068431A4 (fr) Méthodes et compositions pour le traitement du cytomégalovirus humain
EP3016981A4 (fr) Compositions et méthodes pour traiter un accident vasculaire cérébral
HK1225971A1 (zh) 使用拉喹莫德治療青光眼

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170705

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/56 20060101AFI20170629BHEP

Ipc: A61K 9/00 20060101ALI20170629BHEP

Ipc: A61K 31/415 20060101ALI20170629BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180201